Here are the 8-K filings from Niki BioSolutions, Inc. (NIKI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow NIKI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NIKI filings page.
Niki BioSolutions, Inc. appointed Thomas Freeburg as Chief Financial Officer on October 9, 2026, for a two-year term commencing September 1, 2026, unless terminated sooner. Freeburg previously served as Chief Financial Officer, Secretary and Treasurer of Interpace Biosciences from February 2021 through March 2023 and is a Certified Public Accountant. His employment agreement provides for a $250,000 base salary, with $25,000 deferred until the company receives certain funding; the base salary increases to $275,000 upon receipt of additional funding. He is eligible for an annual bonus of up to 50% of base salary and the agreement provides for 50,000 stock options at an exercise price of $8.83 per share, with an agreed vesting schedule. Either party may terminate the agreement on 45 days’ notice before the end of the then-current term; the company may remove him for cause to the extent permitted by applicable law.
Niki BioSolutions, Inc. entered into an at-the-market offering agreement allowing it to issue and sell common stock from time to time with an aggregate maximum offering price of up to $1,396,000, subject to the agreement’s limits, available authorized but unissued shares, and the company’s continued eligibility to use Form S-3. H.C. Wainwright & Co., LLC will use commercially reasonable efforts to sell shares as agent at market prices. The company sets a maximum number of shares for each trading day and a minimum sale price; Wainwright may also purchase as principal under a separate terms agreement.
The company has no obligation to sell shares. For sales as agent, it will pay Wainwright 3.0% of the gross sales price and reimburse certain expenses. Dr. Kira Sheinerman, the company’s largest shareholder and a director, is a managing director of Wainwright, which is deemed to have a conflict of interest under FINRA Rule 5121. Brookline Capital Markets, a division of Arcadia Securities, LLC, agreed to act as qualified independent underwriter for no additional compensation.
Niki BioSolutions, Inc. (NIKI) filed a current report to furnish a corporate investor presentation outlining its post-merger strategy and operations. The presentation describes the completed all-stock merger with DiamiR Biosciences Corp., under which DiamiR holds approximately 70% and Aptorum Group holders about 30% of the combined company.
The combined business centers on non-invasive, blood-based diagnostics and pharma services for Alzheimer’s disease and other brain-health indications, built around a CLIA-licensed, CAP-accredited, New York State–licensed laboratory in New Haven, Connecticut and a proprietary microRNA platform. Near-term revenue is expected from pharma services such as APOE genotyping, with the first pharma customer signed and revenue-generating activity described as starting in the third quarter of 2026.
The pipeline includes the CogniMIR® Alzheimer’s risk test (analytically validated, with clinical validation planned in 2027 and more than 2,000 samples collected), APOE genotyping, and proof-of-concept tests for Rett syndrome, glioblastoma and Long-COVID, plus early-stage therapeutic candidates. The presentation cites external estimates that the Alzheimer’s diagnostics market could grow from $9.2 billion in 2025 to $21.5 billion in 2035 and emphasizes that many statements are forward-looking and not guarantees of future results.
Niki BioSolutions, Inc. (NIKI) disclosed new executive arrangements following its previously announced merger. Ian Huen is serving as Chief Executive Officer under an appointment letter effective August 1, 2026, with an initial six‑month term and a monthly base salary of HKD 210,000 (approximately USD 26,800). He is eligible for discretionary cash bonuses, share bonuses and stock options under the company’s share option plan, and either party may terminate his appointment with one month’s notice, subject to specified events.
Alidad Mireskandari will serve as President and Chief Operating Officer under an employment agreement dated September 1, 2026, with an annual base salary of USD 320,000, including USD 35,000 deferred until the company receives capital investments resulting in USD 3,000,000 of proceeds. His base salary increases to USD 350,000 if aggregate capital investments reach USD 5,000,000 during his employment. He is eligible for an annual performance bonus of up to 50% of base salary, received 20,000 RSUs that vested at the merger closing, and options to purchase 800,000 shares under the 2026 Equity Incentive Plan, subject to vesting conditions.
Niki BioSolutions, Inc. (NIKI) filed an amended report to add audited financials for its acquired subsidiary DiamiR Biosciences Corp. and unaudited pro forma combined financial information following their July 20, 2026 merger and Aptorum’s domestication and name change to Niki.
For the years ended May 31, 2026 and 2025, DiamiR reported revenue of $190,355 and $631,729 and net losses of $659,936 and $743,235, respectively. As of May 31, 2026, DiamiR had total assets of $618,078, total liabilities of $2,211,981 and a stockholders’ deficit of $1,593,903, including $1,314,150 of related-party convertible notes payable and a $65,000 loan from Aptorum.
DiamiR’s auditors and management highlight a going concern uncertainty due to recurring losses, negative cash flows and the need for additional capital. Purchase price allocation records $8.24 million of patents, $6.78 million of in-process R&D, $1.58 million of tradename assets and $1.08 million of goodwill. Pro forma, the combined company shows net losses of $2.05 million for the six months ended June 30, 2026 and $3.60 million for 2025.
Niki BioSolutions, Inc. (NIKI) furnished unaudited consolidated financial statements for the six months ended June 30, 2026, in connection with its transition from foreign private issuer to domestic issuer status and to update its existing registration statements. The company reported a net loss of $1.31 million, no revenue, and operating cash outflow of $1.55 million. Cash declined to $1.83 million with negative working capital of $2.48 million and an accumulated deficit of $75.12 million, while long-term non-marketable investments, primarily in Alzheon, remained at $15.10 million and are pledged against a related-party convertible note.
Management concluded that recurring losses, limited liquidity and DiamiR’s financial profile raise substantial doubt about the group’s ability to continue as a going concern. On July 20, 2026, after the reporting date, Aptorum completed its domestication to Delaware, changed its name to Niki BioSolutions, closed the merger with DiamiR Biosciences Corp., and issued 1,979,216 Niki common shares to DiamiR stockholders and 814,375 common shares plus 179,693 Series A preferred shares to existing Aptorum shareholders. Warrant liabilities decreased from $306,000 to $142,000, generating a fair value gain, and the company disclosed an ongoing lawsuit in U.S. federal court that it is contesting.